— Know what they know.
Not Investment Advice
Also trades as: INDV.L (LSE) · $vol 5M

INDV NASDAQ

Indivior Pharmaceuticals Inc
1W: -0.1% 1M: -5.9% 3M: -13.4% YTD: -2.8% 1Y: +38.2% 3Y: +86.7% 5Y: +115.7%
$34.72
+0.16 (+0.46%)
 
Weekly Expected Move ±4.8%
$31 $33 $34 $36 $38
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Sell · Power 42 · $4.3B mcap · 109M float · 2.00% daily turnover · Short 52% of daily vol
Credit Risk of going bust: lower than 74% of companies Debt: 10.5% of company value Bonds: $90.4M held by 58 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.31 (down 99.1%), Indivior Pharmaceuticals Inc would be worth roughly what it owes.
Total debt $509.0M against a stock market value of $4.33B.
Distance to default 8.38 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $252.5M (short-term plus half of long-term), stock volatility 36.3%; Altman Z 3.49. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

ESG Scores — INDV

Company vs Sector Average

Historical ESG Trend

View All ESG Filings (13)
Date Form Environmental Social Governance ESG Score Filing
2026-06-30 10-Q 64.9 56.1 63.0 61.3 SEC ↗
2026-03-31 10-Q 70.4 54.7 60.6 61.9 SEC ↗
2025-12-31 10-K 60.0 56.2 56.8 57.6 SEC ↗
2025-09-30 10-Q 63.5 63.3 73.3 66.7 SEC ↗
2025-06-30 10-Q 64.7 64.9 72.6 67.4 SEC ↗
2025-03-31 10-Q 72.1 62.8 77.7 70.9 SEC ↗
2024-12-31 10-K 57.5 57.6 60.2 58.5 SEC ↗
2024-09-30 6-K 62.8 64.5 53.0 60.1 SEC ↗
2024-06-30 6-K 62.5 65.1 60.2 62.6 SEC ↗
2024-03-31 6-K 63.0 65.9 56.4 61.8 SEC ↗
2023-12-31 20-F 57.7 59.0 58.2 58.3 SEC ↗
2023-09-30 6-K 64.3 68.3 59.9 64.2 SEC ↗
2023-06-30 6-K 46.8 61.9 63.1 57.2 SEC ↗

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms